A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CV 8102 (Primary) ; HepaVac 101 (Primary) ; Cyclophosphamide
Indications Carcinoma; Liver cancer
Focus Adverse reactions; First in man; Pharmacodynamics
Acronyms HepaVac101

Most Recent Events

14 Apr 2022 Results published in the Clinical Cancer Research
26 Jun 2021 Results presented at The International Liver Congress 2021
29 Aug 2020 Results presented at The International Liver Congress 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight